CRISPR-Cas genome editing in cell culture systems is a powerful technique for disease modeling and the development of cellular therapies. Compared to work with immortalized cell lines, genome editing of stem and primary cells presents unique challenges, including issues related to efficient delivery and expression of CRISPR machinery, clonogenicity, and cytotoxicity. In this webinar, our in-house expert, Dr. Ashley Watson, discusses optimized workflows for CRISPR-Cas9 genome editing in human pluripotent stem cells and primary T cells.
To view the webinar, please complete the form, or sign in to your account.
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.